Miller Value Partners LLC Makes New Investment in Bristol Myers Squibb Company $BMY

Key Points

• Miller Value Partners acquired 69,500 Bristol Myers Squibb shares in the second quarter, valued at approximately $4.0 million. Institutional investors and hedge funds collectively own 76.41% of BMY.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of $66.06, though recent calls ranged from “Buy” to “Neutral” and “Equal Weight.”
• Bristol Myers Squibb exceeded quarterly expectations with $2.04 in adjusted EPS and $12.97 billion in revenue, while reporting a quarterly dividend of $0.63 per share, equivalent to a 3.7% annualized yield.

Miller Value Partners LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 69,500 shares of the biopharmaceutical company's stock, valued at approximately $4,005,000.

Other institutional investors have also added to or reduced their stakes in the company. Davis Asset Management L.P. acquired a new position in Bristol Myers Squibb during the second quarter worth approximately $27,000. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. raised its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 202 shares during the period. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at $25,000. Finally, Addison Advisors LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an "equal weight" rating in a report on Friday, July 31st. TD Cowen began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating for the company. Argus raised shares of Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target on the stock in a report on Wednesday, August 5th. BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $67.86 on Wednesday. The firm has a 50-day moving average price of $61.01 and a two-hundred day moving average price of $59.54. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a market capitalization of $138.62 billion, a P/E ratio of 14.95, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business's revenue for the quarter was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.7%. Bristol Myers Squibb's payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source